Susquehanna International Group, LLP Argenx Se Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $26.1 Million - $33.2 Million	-60,200 Reduced 33.11%	121,600 $65.9 Million
Q2 2024 Aug 15, 2024	BUY	$356.01 - $451.55 $45.1 Million - $57.2 Million	126,700 Added 229.95%	181,800 $78.2 Million
Q1 2024 May 07, 2024	SELL	$356.95 - $413.29 $18.5 Million - $21.4 Million	-51,800 Reduced 48.46%	55,100 $21.7 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $4.54 Million - $6.78 Million	-13,400 Reduced 11.14%	106,900 $40.7 Million
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $27.1 Million - $40.3 Million	-73,500 Reduced 37.93%	120,300 $59.1 Million
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $36.1 Million - $42.3 Million	100,100 Added 106.83%	193,800 $75.5 Million
Q1 2023 May 16, 2023	BUY	$334.23 - $403.65 $1.17 Million - $1.41 Million	3,500 Added 3.88%	93,700 $34.9 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $11.8 Million - $13.9 Million	34,600 Added 62.23%	90,200 $34.2 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $6.14 Million - $7.08 Million	17,900 Added 47.48%	55,600 $19.6 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.